Advertisement
Screener

GW PHARMACEUTICALS PLC Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

GW PHARMACEUTICALS PLC Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

GW PHARMACEUTICALS PLC reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$19.68 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-03.

Discontinued › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2021-05-03

  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-03-31 was -$19.68M.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-12-31 was -$29.15M.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-09-30 was -$12.19M.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2020-06-30 was -$8.83M, a 111.07% decline year-over-year.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$58.13M.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$9.02M.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$295.17M.
  • GW PHARMACEUTICALS PLC net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$170.46M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2021-03-31-$19.68M
10-Q · filed 2021-05-03
-$48.82M
derived: sum of 2 quarters · filed 2021-05-03
-$61.01M
derived: sum of 3 quarters · filed 2021-05-03
-$69.84M
derived: sum of 4 quarters · filed 2021-05-03
2020-12-31-$29.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
-$41.34M
derived: sum of 2 quarters · filed 2021-02-26
-$50.16M
derived: sum of 3 quarters · filed 2021-02-26
-$58.13M
10-K · filed 2021-02-26
2020-09-30-$12.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$21.02M
derived: sum of 2 quarters · filed 2020-11-05
-$28.98M
10-Q · filed 2020-11-05
-$53.93M
derived: sum of 4 quarters · filed 2021-05-03
2020-06-30-$8.83M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
-$16.79M
10-Q · filed 2020-08-07
-$41.74M
derived: sum of 3 quarters · filed 2021-05-03
-$55.50M
derived: sum of 4 quarters · filed 2021-05-03
2020-03-31-$7.96M
10-Q · filed 2021-05-03
-$32.91M
derived: sum of 2 quarters · filed 2021-05-03
-$46.67M
derived: sum of 3 quarters · filed 2021-05-03
$33.08M
derived: sum of 4 quarters · filed 2021-05-03
2019-12-31-$24.95M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
-$38.70M
derived: sum of 2 quarters · filed 2021-02-26
$41.05M
derived: sum of 3 quarters · filed 2021-02-26
-$9.02M
10-K · filed 2021-02-26
2019-09-30-$13.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$65.99M
derived: sum of 2 quarters · filed 2020-11-05
$15.93M
10-Q · filed 2020-11-05
-$55.98M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30$79.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$29.68M
10-Q · filed 2020-08-07
-$42.22M
derived: sum of 3 quarters · filed 2021-02-26
-$122.10M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31-$50.06M
10-Q · filed 2020-05-11
-$121.97M
derived: sum of 2 quarters · filed 2021-02-26
-$201.85M
derived: sum of 3 quarters · filed 2021-02-26
-$285.86M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31-$71.91M
10-K · filed 2021-02-26
-$151.78M
derived: sum of 2 quarters · filed 2021-02-26
-$235.80M
derived: sum of 3 quarters · filed 2021-02-26
-$305.26M
derived: sum of 4 quarters · filed 2021-02-26
2018-09-30-$79.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
-$163.89M
derived: sum of 2 quarters · filed 2019-11-06
-$233.35M
10-Q · filed 2019-11-06
-$295.17M
10-K · filed 2021-02-26
2018-06-30-$84.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
-$153.47M
10-Q · filed 2019-08-07
-$215.29M
derived: sum of 3 quarters · filed 2021-02-26
2018-03-31-$69.46M
10-Q · filed 2019-05-08
-$131.28M
derived: sum of 2 quarters · filed 2021-02-26
2017-12-31-$61.82M
10-K · filed 2021-02-26
2017-09-30-$170.46M
10-K · filed 2020-02-27
2016-09-30-$91.70M
10-KT · filed 2019-02-28